Details of the Drug Combination

General Information of Drug Combination (ID: DC3CYMQ)

Drug Combination Name
Paritaprevir Ombitasvir
Indication
Disease Entry Status REF
Hepatitis C Virus Phase 2 [1]
Component Drugs Paritaprevir   DM4N7BT Ombitasvir   DMQIMTK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paritaprevir
Disease Entry ICD 11 Status REF
Hepatitis C 1E51 Approved [2]
Paritaprevir Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]
------------------------------------------------------------------------------------
Indication(s) of Ombitasvir
Disease Entry ICD 11 Status REF
Hepatitis C 1E51 Approved [2]
Ombitasvir Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hepatitis C virus infection DC2FWU4 N. A. Approved [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01458535) A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Nave Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
4 FDA Approved Drug Products from FDA Official Website. 2015. Application Number: (ANDA) 207931.